adriamycinol has been researched along with elacridar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booth, CL; Brouwer, KL; Brouwer, KR | 1 |
| Chandler, LH; de Bruijn, P; Jewell, RC; Loos, WJ; Nooter, K; Paul, EM; Planting, AS; Sparreboom, A; van der Burg, ME; van der Gaast, A; Verweij, J; Wissel, PS | 1 |
1 trial(s) available for adriamycinol and elacridar
| Article | Year |
|---|---|
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Colorectal Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Neutrophils; Tetrahydroisoquinolines; Time Factors | 1999 |
1 other study(ies) available for adriamycinol and elacridar
| Article | Year |
|---|---|
Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Topics: Acridines; Animals; Antibiotics, Antineoplastic; Bile; Dimethyl Sulfoxide; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Half-Life; In Vitro Techniques; Isoquinolines; Liver; Male; Models, Biological; Quinidine; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 1998 |